Education
About Us
Working with TipRanks
Follow Us
Achieve Life Sciences (ACHV)
NASDAQ:ACHV
ACHV Stock Chart & Stats
$4.39
-$0.11(-3.08%)
At close: 4:00 PM EST
$4.39
-$0.11(-3.08%)
Day’s Range― - ―
52-Week Range$1.84 - $6.03
Previous CloseN/A
Volume131.37K
Average Volume (3M)582.10K
Market Cap
$230.50M
Enterprise Value$221.84M
Total Cash (Recent Filing)$48.11M
Total Debt (Recent Filing)$9.96M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Mar 12, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding53,233,990
10 Day Avg. Volume342,232
30 Day Avg. Volume582,103
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)5.40
Price to Sales (P/S)0.00
P/FCF Ratio-3.79
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.90K
Enterprise Value/Ebitda-4.32
Forecast
1Y Price Target
$12.00Price Target Upside173.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.24
Revenue Forecast (FY)$15.81M
Bulls Say, Bears Say
Bulls Say
Competitive PositioningPfizer's choice to distribute an existing cessation product through a direct-to-consumer channel without active marketing could leave Achieve Life Sciences as the principal branded alternative if cytisinicline gains approval.
Market Opportunity And Regulatory SupportCytisinicline's potential application in vaping and smokeless tobacco markets combined with a regulatory priority review voucher could create multiple commercial pathways and enhance revenue prospects.
Pricing And ReimbursementA high out-of-pocket benchmark set by the direct-to-consumer channel could help cytisinicline secure lower insured co-pays over time, improving commercial access through payer coverage.
Bears Say
Commercial Adoption RiskPhysicians and payers may prefer familiar generic therapies over a new branded alternative, which could slow adoption even if the new product demonstrates clinical benefit.
Generic CompetitionMultiple generic varenicline products create a well-established lower-cost option that could limit uptake and market share for a newly launched branded smoking cessation therapy.
Pricing PressureThe presence of generics in the market may force substantial price concessions on any branded entrant, reducing potential revenue and margin for cytisinicline.
Achieve Life Sciences News
ACHV FAQ
What was Achieve Life Sciences’s price range in the past 12 months?
Achieve Life Sciences lowest stock price was $1.84 and its highest was $6.03 in the past 12 months.
What is Achieve Life Sciences’s market cap?
Achieve Life Sciences’s market cap is $230.50M.
When is Achieve Life Sciences’s upcoming earnings report date?
Achieve Life Sciences’s upcoming earnings report date is Mar 12, 2026 which is in 7 days.
How were Achieve Life Sciences’s earnings last quarter?
Achieve Life Sciences released its earnings results on Nov 06, 2025. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.244 by -$0.036.
Is Achieve Life Sciences overvalued?
According to Wall Street analysts Achieve Life Sciences’s price is currently Undervalued.
Does Achieve Life Sciences pay dividends?
Achieve Life Sciences does not currently pay dividends.
What is Achieve Life Sciences’s EPS estimate?
Achieve Life Sciences’s EPS estimate is -0.29.
How many shares outstanding does Achieve Life Sciences have?
Achieve Life Sciences has 53,233,990 shares outstanding.
What happened to Achieve Life Sciences’s price movement after its last earnings report?
Achieve Life Sciences reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.244. Following the earnings report the stock price went down -3.854%.
Which hedge fund is a major shareholder of Achieve Life Sciences?
Currently, no hedge funds are holding shares in ACHV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Achieve Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (173.35% Upside)
$12.00 (173.35% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 42.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.48%
12-Months-Change
Fundamentals
Return on Equity
-161.08%
Trailing 12-Months
Asset Growth
8.60%
Trailing 12-Months
Company Description
Achieve Life Sciences
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
ACHV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant regulatory achievements and strategic advancements, particularly in gaining an expedited review for vaping cessation. However, funding needs for further clinical trials and challenges in aligning commercial strategies for two different market entries pose potential risks.View all ACHV earnings summariesACHV Stock 12 Month Forecast
Average Price Target
$12.00
▲(173.35% Upside)
Technical Analysis
Ownership Overview
1.68% Insiders
8.07% Mutual Funds
9.51% Other Institutional Investors
74.38% Public Companies and
Individual Investors